Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Is Tadalafil recalled?

Yes — there is an active recall. 6 ongoing FDA recalls mention Tadalafil (25 total). Check the affected lots below.

Most common reason: cGMP deviation (18 of these recalls)

Recalls are matched by product description. A recall usually affects specific lots, not every package of Tadalafil. “Active” means an FDA recall is still ongoing; “closed” means it was terminated or completed. Checked against openFDA on Oct 10, 2026.

Tadalafil recalls in 2026

3 initiated in 2026, 25 in total — newest first
Class II · Moderate risk

Tadalafil USP

CGMP Deviations:Noted during FDA inspection

Ongoing cGMP deviation Shoolin Pharma Chem LLP NDC 85702-001-08 D-0762-2026
Class II · Moderate risk

Tadalafil USP

CGMP Deviations:Noted during FDA inspection

Ongoing cGMP deviation Shoolin Pharma Chem LLP NDC 85702-002-04 D-0761-2026
Class II · Moderate risk

Tadalafil USP

CGMP Deviations:Noted during FDA inspection

Ongoing cGMP deviation Shoolin Pharma Chem LLP NDC 85702-002-02 D-0760-2026
Class II · Moderate risk

Tadalafil Tablets

cGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection.

Ongoing cGMP deviation Preferred Pharmaceuticals, Inc. NDC 68788-8153-7 D-0526-2023
Class II · Moderate risk

Tadalafil Tablets

CGMP Deviations

Ongoing cGMP deviation Northwind Pharmaceuticals LLC NDC 51655-487-52 D-0554-2023
Class II · Moderate risk

Tadalafil Tablets

CGMP Deviations

Ongoing cGMP deviation Northwind Pharmaceuticals LLC NDC 51655-473-87 D-0553-2023
Class II · Moderate risk

Tadalafil Tablets

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-372-10 D-0417-2023
Class II · Moderate risk

Tadalafil Tablets

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-371-10 D-0416-2023
Class II · Moderate risk

Tadalafil Tablets

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-370-10 D-0415-2023
Class II · Moderate risk

Tadalafil Tablets

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-369-10 D-0414-2023
Class II · Moderate risk

Tadalafil Tablets

Incorrect Product Formulation: An incorrect grade of Crospovidone was used to manufacture the product.

Terminated cGMP deviation Sun Pharmaceutical Industries INC NDC 16714-077-01 D-0231-2022
Class II · Moderate risk

Tadalafil Tablets

Incorrect Product Formulation: An incorrect grade of Crospovidone was used to manufacture the product.

Terminated cGMP deviation Sun Pharmaceutical Industries INC NDC 16714-075-01 D-0230-2022
Class II · Moderate risk

Tadalafil 7 mg Capsule

Lack of Processing Controls (lack of assurance of conformity to specifications).

Terminated cGMP deviation MasterPharm LLC D-1440-2020
Class II · Moderate risk

Tadalafil 3 mg Capsule

Lack of Processing Controls (lack of assurance of conformity to specifications).

Terminated cGMP deviation MasterPharm LLC D-1439-2020
Class II · Moderate risk

Tadalafil 26 mg Capsule

Lack of Processing Controls (lack of assurance of conformity to specifications).

Terminated cGMP deviation MasterPharm LLC D-1438-2020
Class II · Moderate risk

Tadalafil 18 mg Capsule

Lack of Processing Controls (lack of assurance of conformity to specifications).

Terminated cGMP deviation MasterPharm LLC D-1437-2020
Class II · Moderate risk

Tadalafil 12 mg Capsule

Lack of Processing Controls (lack of assurance of conformity to specifications).

Terminated cGMP deviation MasterPharm LLC D-1436-2020
Class II · Moderate risk

Tadalafil 6 mg Capsule

Labeling: Incorrect or missing lot and/or expiration date. Products were compounded using expired components.

Terminated Labeling / mix-up MPRX, Inc. dba Medical Park Pharmacy D-0819-2020
Class II · Moderate risk

Tadalafil 20 mg Troche

Labeling: Incorrect or missing lot and/or expiration date. Products were compounded using expired components.

Terminated Labeling / mix-up MPRX, Inc. dba Medical Park Pharmacy D-0818-2020
Class II · Moderate risk

Tadalafil USP

CGMP Deviations: Lack of stability data and controls to support the manufacturers assigned retest or expiration date in firm's container/closure system.

Terminated Stability / shelf life American Pharmaceutical Ingredients LLC NDC 58597-8538-2 D-0524-2018
Class II · Moderate risk

Tadalafil Citrate active pharmaceutical ingredient packaged in…

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-912-2015
Class II · Moderate risk

Tadalafil active pharmaceutical ingredient packaged in varying…

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-911-2015